The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy

SDHA Loss-of-Function Mutations in KIT-PDGFRA Wild-Type Gastrointestinal Stromal Tumors Identified by Massively Parallel Sequencing

(2011) M. A. Pantaleo et al.   JNCI-Journal of the National Cancer Institute

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

(2010) P. Hohenberger et al.   BRITISH JOURNAL OF SURGERY

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

(2010) Axel Le Cesne et al.   EUROPEAN JOURNAL OF CANCER

Kitlow Stem Cells Cause Resistance to Kit/Platelet-Derived Growth Factor α Inhibitors in Murine Gastrointestinal Stromal Tumors

(2010) Michael R. Bardsley et al.   GASTROENTEROLOGY

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours

(2010) Marco Novelli et al.   HISTOPATHOLOGY

Imatinib treatment of metastatic GIST: don't stop (believing)

(2010) Michael C Heinrich   LANCET ONCOLOGY

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations

(2010) K. A. Janeway et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DOG1 Antibody in the Differential Diagnosis of Gastrointestinal Stromal Tumors

(2009) Markku Miettinen et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

(2009) M. Montemurro et al.   EUROPEAN JOURNAL OF CANCER

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictors of Competing Mortality in Advanced Head and Neck Cancer

(2009) Loren K. Mell et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

(2009) Jason S Gold et al.   LANCET ONCOLOGY

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

(2008) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

Risk stratification of patients diagnosed with gastrointestinal stromal tumor

(2008) Heikki Joensuu   HUMAN PATHOLOGY

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

(2008) B Liegl et al.   JOURNAL OF PATHOLOGY

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

(2008) Burton L. Eisenberg et al.   JOURNAL OF SURGICAL ONCOLOGY

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)

(2007) Ronald P. DeMatteo et al.   CANCER